Adult Open Studies

Biology

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Mark E. Reeves, MD, PhD
Champions Oncology
Refer to separate attachment for list of "Tumors of High Interest"; this is included within the LLUCC Biospecimen Laboratory study above
Mark E. Reeves, MD, PhD

Bladder

UroGen- BL013
Phase 3, Single-Arm, Multicenter Study to evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102 for the Treatment of Patients with Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
https://clinicaltrials.gov/study/NCT06331299
Brian Hu, MD

Breast

SWOG-NRG-BR009
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/ HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) 
 
Roshni Narurkar, MD, MBBS 
Syndevrx SDX-0103
A Phase 1b/2 Study Assessing The Safety And Efficacy of Evexomostat (Sdx-7320) In Combination With The Pi3kα Inhibitor alpelisib (Piqray®) Plus Fulvestrant In Postmenopausal Women At Risk For Hyperglycemia With Advanced Breast Cancer And A Pik3ca Mutation Who Have Progressed On Or Following Endocrine Therapy Plus A Cdk4/6 Inhibitor
Gayathri Nagaraj, MD
EMBER-4 E-Lilly – J2J-MC-JZLH
A Randomized, Open Label, Phase 3 Study of Adjuvant imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have previously received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2-Early Breast Cancer with an Increased Risk of Recurrence.
https://classic.clinicaltrials.gov/ct2/show/NCT05514054
Gayathri Nagaraj, MD
SWOG -S2212
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast (SCARLET), A Randomized Phase III Study  
https://classic.clinicaltrials.gov/ct2/show/NCT05929768
Gayathri Nagaraj, MD
SWOG-S2206
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
https://clinicaltrials.gov/study/NCT06058377
Gayathi Nagaraj, MD

COVID-19

Germ Cell

4T-22-2-MAGESTIC
Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –( MAGESTIC Trial: MiRNA in detecting Active Germ Cell tumors in Early Suspected and metastaTIC disease trial)
https://clinicaltrials.gov/study/NCT06060873/a>
Muhannad Alsyouf, MD

GI

Esophageal

Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
Gary Yang, MD

Pancreas

INV INT-Pancreatic - 5170277
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma
https://www.clinicaltrials.gov/ct2/show/NCT03492671
Naveenraj Solomon, MD

Liver

Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases 
https://clinicaltrials.gov/ct2/show/NCT01697371
Gary Yang, MD

GU

GYN

Ovarian/ Peritoneum

SWOG-NRG-GY019
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
https://www.clinicaltrials.gov/ct2/show/NCT04095364
Yevgeniya Ioffe, MD

Lung

NSCLC

SWOG-LUNGMAP
A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
https://www.clinicaltrials.gov/ct2/show/NCT02154490
Hamid Mirshahidi, MD

NSCLC

SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
Hamid Mirshahidi, MD

NSCLC

SWOG-S1900J
A Phase II Study of Amivantamab SC (Subcutaneous) Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Lung Cancer (Lung-MAP Sub-Study)
https://clinicaltrials.gov/study/NCT06116682
Hamid Mirshahidi, MD

NSCLC

SWOG-S1900G
A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant , MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung Map Sub-Study) 
https://clinicaltrials.gov/study/NCT0564257
Hamid Mirshahidi, MD

Melanoma

Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
Jukes Namm, MD

Multiple

COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors (Ages 26+ - Primary tumor arising in testis, ovary, retro-peritoneum or mediastinum)
Albert Kheradpour, MD

Solid Tumors

AMGEN-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (Codebreak 101 Subprotocol H)
https://clinicaltrials.gov/study/NCT04185883
Hamid Mirshahidi, MD
INV-INT-PRESERVE
Phase II Randomized Single-Blinded Trial of Patient Reported Experiences with Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy (PRESERVE Trial)
https://clinicaltrials.gov/study/NCT06828185

Transplant

PTLD

ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
Dr. Sajad Khazal